FGF23 and kidney disorder: Both cardiovascular and kidney disease have a broad spectrum of etiologies and clinical presentation, but during progression of each disease, two hallmarks are an activation of the renin–angiotensin–aldosterone system (RAS), and a rise in serum concentrations of fibroblast growth factor 23 (FGF23) [1].